Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer
Benjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Reinhard Dummer, Shibing Deng, Tao Xie, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer
Benjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Reinhard Dummer, Shibing Deng, Tao Xie, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
Page
of 10